Physician profile
Surinder J Singh
NPI 1184984502
$1,339.91
in general payments reported to CMS, 2019-2025
10 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.17 · 2024: $279 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Consulting Fee: $150 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.75 |
| Consulting Fee | $150.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $565.73 | 2024-2025 | |
| Harmony Biosciences LLC | $259.05 | 2025 | |
| Axsome Therapeutics, INC. | $204.03 | 2024-2025 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.03 | 2022-2025 | Caplyta |
| Abbvie INC. | $89.31 | 2025 | |
| Zoll Respicardia, INC. | $41.81 | 2024 | Remede System |
| Alkermes, INC. | $22.21 | 2022 | |
| Lundbeck LLC | $16.82 | 2022 | |
| Lilly USA, LLC | $14.66 | 2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $14.26 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.